论文降重
免费查重- 钛学术文献服务平台 \
- 学术期刊 \
- 医药卫生科技期刊 \
- 临床医学期刊 \
- 世界临床肿瘤学杂志：英文版期刊 \
Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses
Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses
基本信息来源于合作网站，原文需代理用户跳转至来源网站获取
摘要：
BACKGROUND Immune checkpoint inhibitors(ICPi)cause various immune-related adverse events(irAE)with thyroid dysfunction as a commonly reported abnormality.There is increasing evidence showing positive association with development of irAE and survival.However,prior trials with ICPi had underrepresentation of minorities with<5%African Americans.AIM To evaluate the association between development of irAE and survival outcomes among a racially diverse patient population.METHODS Data on patients with stage IV solid malignancies treated with programmed cell death-protein 1/programmed death ligand 1 blockers between January 2013 and December 2018 across MedStar Georgetown Cancer Institute facilities were retrospectively reviewed.Patients treated with cytotoxic T-lymphocyte-associated protein 4 inhibitors were excluded.Progression free survival(PFS)and overall survival(OS)were primary endpoints and were calculated using Kaplan-Meier methods and Wilcoxon rank sum test for comparison.RESULTS Out of 293 patients who met eligibility criteria,91 pts(31%)had any grade irAE;most common AE were endocrine(40.7%)specifically TSH elevation,dermatological(23.1%)and rheumatologic(18.7%).Proportion of irAE was significantly higher in Caucasians vs African Americans(60.4%vs 30.8%),in patients with low programmed death ligand 1,lower LDH,older age,and those who had more treatment cycles with ICPi.Rate of progression was lower in patients with irAE(30.8%vs 46.0%,P=0.0140).Median PFS(5.8 vs 3.0 mo,P=0.0204)and OS(17.1 vs 7.2 mo,P<0.0001)were higher with irAE.Statistically significant difference in OS(17.1 vs 8.6 mo,P=0.0002)but not in PFS(5.8 vs 3.3 mo,P=0.0545)was noted with endocrine irAE.No differences in survival were observed among other commonly reported irAE.Differences in survival among subgroups of patients with irAE are described.CONCLUSION Development of irAE positively correlated with improved PFS and OS as reported in previous studies.To our knowledge,this is the first study observing differences in OS favoring endocrine AE an
推荐文章
免疫检查点抑制剂风湿性毒副反应诊治建议
免疫检查点抑制剂
免疫相关副反应
风湿性疾病
治疗
免疫检查点抑制剂治疗恶性肿瘤的不良反应及处理
恶性肿瘤
免疫检查点抑制剂
免疫治疗相关不良反应
免疫检查点抑制剂相关感染诊治建议
免疫检查点
PD-1/PD-L1抑制剂
免疫治疗相关不良事件
感染
免疫检查点抑制剂相关性重症肌无力:从诊断到治疗
免疫检查点抑制剂
重症肌无力
外周神经病变
免疫治疗不良反应
内容分析
关键词云
关键词热度
相关文献总数
(/次)
(/年)
文献信息
| 篇名 | Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses | ||
| 来源期刊 | 世界临床肿瘤学杂志:英文版 | 学科 | 医学 |
| 关键词 | IMMUNOTHERAPY Adverse events ENDOCRINE SURVIVAL Race MINORITY | ||
| 年，卷（期） | 2021,（2） | 所属期刊栏目 | |
| 研究方向 | 页码范围 | 103-114 | |
| 页数 | 12页 | 分类号 | R73 |
| 字数 | 语种 | ||
| DOI | |||
五维指标
引文网络
引文网络
二级参考文献 (0)
共引文献 (0)
参考文献 (0)
节点文献
引证文献 (0)
同被引文献 (0)
二级引证文献 (0)
2021(0)
- 参考文献(0)
- 二级参考文献(0)
- 引证文献(0)
- 二级引证文献(0)
研究主题发展历程
节点文献
IMMUNOTHERAPY
Adverse
events
ENDOCRINE
SURVIVAL
Race
MINORITY
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
世界临床肿瘤学杂志：英文版
主办单位：
百世登出版集团有限公司
出版周期：
不定期
ISSN：
2218-4333
CN：
开本：
出版地：
北京市朝阳区东四环中路62号楼远洋国际中
邮发代号：
创刊时间：
语种：
出版文献量（篇）
44
总下载数（次）
0
总被引数（次）
0
期刊文献
相关文献
推荐文献
